FITC Anti-Vaccinia Virus antibody (ab19970)
Key features and details
- FITC Rabbit polyclonal to Vaccinia Virus
- Suitable for: ICC/IF
- Reacts with: Vaccinia virus
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG
Overview
-
Product name
FITC Anti-Vaccinia Virus antibody
See all Vaccinia Virus primary antibodies -
Description
FITC Rabbit polyclonal to Vaccinia Virus -
Host species
Rabbit -
Conjugation
FITC. Ex: 493nm, Em: 528nm -
Specificity
Ab19970 recognizes purified virions. -
Tested applications
Suitable for: ICC/IFmore details -
Species reactivity
Reacts with: Vaccinia virus -
Immunogen
Lister strain (mixture of virions and infected cell polypeptides)
-
General notes
IgG fraction covalently coupled with high purity Isomer I of fluorescein isothiocyanate.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
Preservative: 0.1% Sodium azide
Constituents: 0.0268% PBS, 1% BSA -
Concentration information loading... -
Purity
Protein A purified -
Purification notes
Care is taken to ensure complete removal of any free fluorescein from the final product. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab19970 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF | Use at an assay dependent dilution. |
Target
-
Relevance
Vaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process. -
Alternative names
- A27L antibody
- Orthopoxvirus antibody
Protocols
References (4)
ab19970 has been referenced in 4 publications.
- Chen W et al. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. Oncol Rep 41:67-76 (2019). PubMed: 30365143
- Lauron EJ et al. Viral MHCI inhibition evades tissue-resident memory T cell formation and responses. J Exp Med 216:117-132 (2019). PubMed: 30559127
- Hou W et al. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. Int J Cancer 135:1238-46 (2014). PubMed: 24474587
- Li Z et al. A flow cytometry-based immuno-titration assay for rapid and accurate titer determination of modified vaccinia Ankara virus vectors. J Virol Methods 169:87-94 (2010). PubMed: 20637240
